Flashpoint Therapeutics
Flashpoint Therapeutics is a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines. Their platform enables targeted therapies that co-deliver therapeutic components directly to individual cells, enhancing drug delivery, stability, potency, and safety. They focus on modalities like mRNA, DNA, proteins, and CRISPR, with a validated platform demonstrating safety and efficacy, including complete remissions in late-stage cancer. The company advances a pipeline of first-in-class nanomedicines through internal development and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Patents
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US-11957788-B2
View DetailsLiposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
US-11866700-B2
View DetailsMultivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US-11123294-B2
View DetailsSpherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US-10894963-B2
View DetailsSpherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US-10837018-B2
View Details
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US-11957788-B2
View DetailsLiposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
US-11866700-B2
View DetailsMultivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US-11123294-B2
View DetailsSpherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US-10894963-B2
View DetailsSpherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US-10837018-B2
View DetailsProducts
Modular structural nanomedicine platform
A modular nanoscale formulation platform that assembles structural nanotherapeutics capable of precise payload stoichiometry, synchronized activation kinetics, and targeted cellular uptake.
Modular structural nanomedicine platform
A modular nanoscale formulation platform that assembles structural nanotherapeutics capable of precise payload stoichiometry, synchronized activation kinetics, and targeted cellular uptake.
Services
Partnership-based access to a modular nanostructure discovery and formulation platform to co-develop therapeutic candidates combining nucleic acids, peptides, proteins, or small molecules.
Manufacturing and CMC support to produce development candidates at clinical scale under GMP conditions suitable for human studies.
Partnership-based access to a modular nanostructure discovery and formulation platform to co-develop therapeutic candidates combining nucleic acids, peptides, proteins, or small molecules.
Manufacturing and CMC support to produce development candidates at clinical scale under GMP conditions suitable for human studies.
Expertise Areas
- Nanomedicine design and formulation
- Intracellular and targeted delivery
- Immuno-oncology therapeutic development
- Nucleic acid and peptide therapeutics
Key Technologies
- Structural nanomedicines
- Nanoparticle co-delivery systems
- Controlled activation kinetics
- Nucleic acid therapeutics (mRNA/DNA/siRNA)